Nasdaq:US$18.73 (+0.01) | HKEX:HK$30.75 (+1.05) | AIM:£2.96 (-0.08)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 18 Feb 2017

ASCO GU 2017: Savolitinib Phase II in advanced papillary renal cell cancer

A Single-Arm Biomarker-Based Phase II Trial of Savolitinib in Patients with Advanced Papillary Renal Cell Cancer

Toni K. Choueiri, Elizabeth Plimack, Hendrik-Tobias Arkenau, Eric Jonasch, Daniel Y. C. Heng, Thomas Powles, Melanie M. Frigault, Edwin Clark, Amir Handzel, Humphrey Gardner, Shethah Morgan, Laurence Albiges, Sumanta Kumar Pal

Event: Genitourinary Cancers Symposium sponsored by the American Society of Clinical Oncology (ASCO GU)

Abstract No: 436

Session: Session C: Penile, Urethral, and Testicular Cancers; Renal Cell Cancer

Date: Saturday, February 18, 2017

Time: 7:00 AM-7:55 AM and 11:30 AM-1:00 PM (EST)